Vitamin D receptor expression in invasive breast tumors and breast cancer survival

Breast Cancer Research

Table 3 Vitamin D receptor expression in relation to breast cancer mortality stratified by surrogate molecular subtypes

Surrogate molecular subtype	Nuclear VDR fraction	n	Person-years	Dead from breast cancer	Breast cancer mortality/100 000	HR^a	HR^a,*	HR^b	HR^b,*	HR^c	HR^c,*
Luminal A-like	0–10%	19	275	4	1455	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
Luminal A-like	11–100%	269	3132	23	734	0.56 (0.19–1.62)	0.76 (0.27–2.14)	0.44 (0.15–1.31)	0.61 (0.21–1.76)	0.79 (0.24–2.63)^d	0.76 (0.32–2.53)^d
Luminal B-like	0–10%	33	325	11	3381	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
Luminal B-like	11–100%	96	1125	15	1334	0.38 (0.18–0.84)	0.37 (0.18–0.76)	0.42 (0.19–0.93)	0.36 (0.17–0.73)	0.43 (0.19–0.94)^e	0.37 (0.18–0.77)^e
HER 2 positive	0–10%	10	82	3	3639	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
HER 2 positive	11–100%	45	436	12	2751	0.78 (0.22–2.79)	0.82 (0.25–2.64)	0.74 (0.20–2.74)	0.73 (0.22–2.47)	1.13 (0.31–4.09)^d	1.00 (0.30–3.33)^d
Triple negative	0–10%	40	419	10	2388	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
Triple negative	11–100%	11	123	3	2440	1.04 (0.28–3.77)	0.85 (0.25–2.86)	0.80 (0.21–3.00)	0.70 (0.21–2.37)	0.87 (0.23–3.19)^e	0.78 (0.23–2.61)^e

^aCrude analysis
^bAdjusted for age at and season of diagnosis
^cHazard ratio adjusted for covariate most affecting the estimate: ^dlymph node status and ^eseason of diagnosis
*Multiple imputation performed to include individuals with missing data on molecular subtype

ISSN: 1465-542X